Cost-effectiveness analysis of burning mouth syndrome therapy

Community Dentistry and Oral Epidemiology

Volumn 40, Issue 2, 2012, Pages 185-192

  Hens, Manuel J ^a   Alonso Ferreira, Veronica ^a   Villaverde Hueso, Ana ^a,b   Abaitua, Ignacio ^a,b   Posada De La Paz, Manuel ^a,b,c  

^a Instituto de Salud Carlos III   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c NONE   (Spain)

Author keywords

burning mouth; cost effectiveness; economics; pharmacoeconomic analysis; therapy

Indexed keywords

EID: 84859108300     PISSN: 03015661     EISSN: 16000528     Source Type: Journal    
DOI: 10.1111/j.1600-0528.2011.00645.x     Document Type: Article

References (46)

1. Merskey H, Bogduk N, eds. Classification of chronic pain: descriptions of chronic pain syndromes and definitions of pain terms/prepared by the task force on taxonomy of the international association for the study of pain, 2nd edn. Seattle: International Association for the Study of Pain Press; 1994; 742.
2. Buchanan J, Zakrzewska J,. Burning mouth syndrome. Clin Evid (Online) 2008; 2008: 1301.
3. Grushka M, Epstein JB, Gorsky M,. Burning mouth syndrome. Am Fam Physician 2002; 65: 615-20.
4. Mock D, Chugh D,. Burning mouth syndrome. Int J Oral Sci 2010; 2: 1-4.
5. Torgerson RR,. Burning mouth syndrome. Dermatol Ther 2010; 23: 291-8.
6. Zakrzewska JM, Forssell H, Glenny AM,. Interventions for the treatment of burning mouth syndrome: a systematic review. J Orofac Pain 2003; 17: 293-300. (Pubitemid 37431287)
7. List T, Axelsson S, Leijon G,. Pharmacologic interventions in the treatment of temporomandibular disorders, atypical facial pain, and burning mouth syndrome: a qualitative systematic review. J Orofac Pain 2003; 17: 301-10. (Pubitemid 37431288)
8. Petruzzi M, Lauritano D, De Benedittis M, Baldoni M, Serpico R,. Systemic capsaicin for burning mouth syndrome: short-term results of a pilot study. J Oral Pathol Med 2004; 3: 111-4. (Pubitemid 38166430)
9. Sardella A, Lodi G, Demarosi F, Tarozzi M, Canegallo L, Carrassi A,. Hypericum perforatum extract in burning mouth syndrome: a randomized placebo-controlled study. J Oral Pathol Med 2008; 37: 395-401.
10. Suda S, Takagai S, Inoshima-Takahashi K, Sugihara G, Mori N, Takei N,. Electroconvulsive therapy for burning mouth syndrome. Acta Psychiatr Scand 2008; 118: 503-4.
11. Fedele S, Fricchione G, Porter SR, Mignogna MD,. Burning mouth syndrome (stomatodynia). Q J Med 2007; 100: 527-30. (Pubitemid 47241919)
12. Maina G, Vitalucci A, Gandolfo S, Bogetto F,. Comparative efficacy of SSRIs and amisulpride in burning mouth syndrome: a single-blind study. J Clin Psychiatry 2002; 63: 38-43. (Pubitemid 34113485)
13. Gremeau-Richard C, Woda A, Navez ML, Attal N, Bouhassisa D, Gognieu MC,. Topical clonazepam in stomatodynia: a randomised placebo-controlled study. Pain 2004; 108: 51-7. (Pubitemid 38251673)
14. Reit C, Gröndahl HG,. Management of periapical lesions in endodontically treated teeth. A study on clinical decision making. Swed Dent J 1984; 8: 1-7.
15. Tulloch JF, Antczak AA, Wilkes JW,. The application of decision analysis to evaluate the need for extraction of asymptomatic third molars. J Oral Maxillofac Surg 1987; 45: 855-63.
16. Maryniuk GA, Schweitzer SO, Braun RJ,. Replacement of amalgams with crowns: a cost-effectiveness analysis. Community Dent Oral Epidemiol 1988; 16: 263-7.
17. Tsevat J, Durand-Zaleski I, Pauker SG,. Cost-effectiveness of antibiotic prophylaxis for dental procedures in patients with artificial joints. Am J Public Health 1989; 79: 739-43. (Pubitemid 19142914)
18. McCreery AM, Truelove E,. Decision making in dentistry. Part I: A historical and methodological overview. J Prosthet Dent 1991; 65: 447-51.
19. Balevi B, Shepperd S,. The management of an endodontically abscessed tooth: patient health state utility, decision-tree and economic analysis. BMC Oral Health 2007; 7: 17.
20. Balevi B,. The management of incipient or suspicious occlusal caries: a decision-tree analysis. Community Dent Oral Epidemiol 2008; 36: 392-400.
21. Listl S, Tu YK, Faggion CM Jr,. A cost-effectiveness evaluation of enamel matrix derivatives alone or in conjunction with regenerative devices in the treatment of periodontal intra-osseous defects. J Clin Periodontol 2010; 37: 920-7.
22. Listl S, Faggion CM Jr,. An economic evaluation of different sinus lift techniques. J Clin Periodontol 2010; 37: 777-87.
23. Popelut A, Rousval B, Fromentin O, Feghali M, Mora F, Bouchard P,. Tooth extraction decision model in periodontitis patients. Clin Oral Implants Res 2010; 21: 80-9.
24. Tulloch JF, Antczak-Bouckoms AA,. Decision analysis in the evaluation of clinical strategies for the management of mandibular third molars. J Dent Educ 1987; 51: 652-60.
25. Scala A, Checchi L, Montevecchi M, Marini I, Giamberardino MA,. Update on burning mouth syndrome: overview and patient management. Crit Rev Oral Biol Med 2003; 14: 275-91. (Pubitemid 44560797)
26. Tan SS, Ken Redekop W, Rutten FF,. Costs and prices of single dental fillings in Europe: a micro-costing study. Health Econ 2008; 17: S83-93. (Pubitemid 351227994)
27. Vademecum internacional, 50th edn. Madrid: UBM Medicom Editorial S.A., UBM Medica Ltd.; 2010; available at: [last accessed 30 September 2011].
28. Capri S, Ceci A, Terranova L, Merlo F, Mantovani L, and The Members of The Italian Group for Pharmacoeconomic Studies. Guidelines for economic evaluations in Italy: recommendations from the Italian group of pharmacoeconomic studies. Drug Inf J 2001; 35: 189-201. (Pubitemid 32198569)
29. Patrick DL, Erickson P,. Health status and health policy. Quality of life in health care evaluation and resource allocation. Oxford: Oxford University Press; 1993.
30. Wennhall I, Norlund A, Matsson L, Twetman S,. Cost-analysis of an oral health outreach program for preschool children in a low socioeconomic multicultural area in Sweden. Swed Dent J 2010; 34: 1-7.
31. Calvert NW, Burch SP, Fu AZ, Reeves P, Thompson TR,. The cost-effectiveness of lamotrigine in the maintenance treatment of adults with bipolar I disorder. J Manag Care Pharm 2006; 12: 322-30. (Pubitemid 47394447)
32. Brisson M, Edmunds WJ,. The cost-effectiveness of varicella vaccination in Canada. Vaccine 2002; 20: 1113-25. (Pubitemid 34135947)
33. Krijnen P, Kaandorp CJ, Steyerberg EW, van Schaardenburg D, Moens HJ, Habbema JD,. Antibiotic prophylaxis for haematogenous bacterial arthritis in patients with joint disease: a cost effectiveness analysis. Ann Rheum Dis 2001; 60: 359-66. (Pubitemid 32242749)
34. The disease control priorities project. Using cost-effectiveness analysis for setting health priorities. Washington: The World Bank Group; 2006; available at: [last accessed 30 September 2011].
35. Barbieri M, Drummond M, Willke R, Chancellor J, Jolain B, Towse A,. Variability of cost-effectiveness estimates for pharmaceuticals in Western Europe: lessons for inferring generalizability. Value Health 2005; 8: 10-23. (Pubitemid 40293637)
36. Drummond M, Barbieri M, Cook J, Glick HA, Lis J, Malik F, et al., Transferability of economic evaluations across jurisdictions: ISPOR Good Research Practices Task Force report. Value Health 2009; 12: 409-18.
37. Le dictionnaire VIDAL 2010. Issy Les Moulineaux: VIDAL; 2010; available at: [last accessed 30 September 2011].
38. Farmacotherapeutisch Kompas. College voor zorgverzekeringen (CVZ); available at: and [last accessed 30 September 2011].
39. Elenco farmaci autorizzati. Agenzia Italiana del Farmaco; available at: [last accessed 30 September 2011].
40. British national formulary, 58th edn, September 2009. London: BMJ Group and RPS Publishing; 2009; available at: and [last accessed 30 September 2011].
41. Lõpez-Jornet P, Camacho-Alonso F, Lucero-Berdugo M,. Quality of life in patients with burning mouth syndrome. J Oral Pathol Med 2008; 37: 389-94.
42. Grushka M, Ching V, Epstein J,. Burning mouth syndrome. Adv Otorhinolaryngol 2006; 63: 278-87. (Pubitemid 44155323)
43. Zakrzewska JM,. Medical management of trigeminal neuropathic pains. Expert Opin Pharmacother 2010; 11: 1239-54.
44. Zakrzewska JM, Forssell H, Glenny AM,. Interventions for the treatment of burning mouth syndrome. Cochrane Database Syst Rev 2005;CD002779. DOI:.
45. Shih YCT, Han S, Cantor SB,. Impact of generic drug entry on cost-effectiveness analysis. Med Decis Making 2005; 25: 71-80. (Pubitemid 40139885)
46. Neumann PJ,. Costing and perspective in published cost-effectiveness analysis. Med Care 2009; 47 (Suppl 1): S28-32.